Format

Send to

Choose Destination
Clin Pharmacol Ther. 2008 Jan;83(1):172-6. Epub 2007 Dec 12.

Cathepsin K inhibitors: a novel target for osteoporosis therapy.

Author information

1
Department of Clinical Pharmacology, Merck Research Laboratories, Rahway, New Jersey, USA. aubrey_stoch@merck.com

Abstract

Osteoporosis is characterized by low bone mass with skeletal fragility and an increased risk of fracture. This bone loss is brought about by an imbalance between bone resorption and formation. Cathepsin K is the most abundant cysteine protease expressed in the osteoclast and is believed to be instrumental in bone matrix degradation necessary for bone resorption. Cathepsin K inhibitors represent a novel target for developing agents to treat osteoporosis and other disorders characterized by increased bone resorption.

PMID:
18073778
DOI:
10.1038/sj.clpt.6100450
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center